Press releases
2025
22 August, 2025
Guard Therapeutics to present at upcoming investor conferences
Guard Therapeutics (publ) today announced that the company will present at the following investor conferences ahead of the upcoming readout of the Phase 2b POINTER study:
21 August, 2025
Guard Therapeutics publishes interim report January–June 2025
The quarter marked a key milestone with the completion of patient recruitment for our Phase 2b POINTER study – ahead of schedule. The positive final safety review reinforces confidence in the trial, underscoring strong momentum and positioning us well for future value creation.
5 June, 2025
Guard Therapeutics announces completion of patient enrollment in Phase 2b POINTER study
Guard Therapeutics (publ) today announced that the last patient has been successfully enrolled in the company’s ongoing Phase 2b clinical trial, POINTER, evaluating the drug candidate RMC-035 as a kidney-protective therapy in patients undergoing open-heart surgery.
27 May, 2025
Guard Therapeutics reports positive outcome from second planned safety review in the Phase 2b POINTER study
Guard Therapeutics today announced that an independent Data Safety Monitoring Committee (DSMC) has completed the second and final planned review of safety data from the ongoing Phase 2b clinical trial, POINTER, which is evaluating the kidney-protective effects of the drug candidate RMC-035 in connection with open-heart surgery. The company...
Guard Therapeutics (publ) today announced that the design of its ongoing Phase 2b clinical trial, POINTER, will be presented at the annual congress of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) in Vienna, Austria.